SpyGlass Pharma buys AVS for $13m to lock in IOL supply
SpyGlass Pharma has acquired Advanced Vision Science (AVS), a California-based intraocular lens (IOL) manufacturer, from Japanese ophthalmic group Santen Pharmaceutical for approximately $13 million in cash. The deal gives SpyGlass direct ownership of the facility already producing the IOLs used in its two ongoing Phase 3 registrational trials of the BIM-IOL System, its lead candidate for glaucoma and ocular hypertension.
AVS has been manufacturing ophthalmic devices since 1975 and holds ISO 13485 quality certification. Its facility is registered with the US FDA and Japan's Ministry of Health, Labour and Welfare. The company is best known for developing what it describes as the first foldable hydrophobic acrylic IOL proven to be free of glistenings, marketed in Japan by Santen as the Eternity lens since 2008 and licensed globally to Bausch + Lomb for its enVista line. Both those commercial relationships will continue under SpyGlass ownership.
What SpyGlass is buying
The BIM-IOL System pairs a novel, non-bioerodible drug pad with a standard IOL, designed to be implanted during routine cataract surgery and deliver three years of sustained bimatoprost release to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Bimatoprost is an FDA-approved prostaglandin analogue that SpyGlass is repurposing into a long-acting format, sidestepping the compliance problems that dog topical eye drops.
Owning the supply chain is a meaningful de-risking step for a company advancing through Phase 3. Contract manufacturing arrangements carry execution risk, and vertical integration ahead of a potential New Drug Application removes a dependency that regulators and investors would otherwise scrutinise. Patrick Mooney, chief executive of SpyGlass Pharma, said the acquisition "secures our long-term supply of world class IOLs" while also opening the door to premium lens options such as toric and extended depth-of-focus designs. The company intends to assess which of those form factors can accommodate its drug delivery pads, potentially extending the addressable market beyond the monofocal segment.
Market context and competitive landscape
The sustained ocular drug delivery space has attracted significant attention over the past several years. Allergan's Bimatoprost SR implant (Durysta) received FDA approval in 2020 and established a regulatory proof-of-concept for intracameral bimatoprost delivery, though it is bioerodible and offers a shorter duration than SpyGlass targets. iDose TR from Glaukos, a titanium micro-implant releasing travoprost, was approved in early 2024, further validating the category. SpyGlass is positioning the BIM-IOL System differently, tying drug delivery to the cataract surgery episode rather than requiring a separate procedure, which could appeal to high-volume cataract surgeons already implanting IOLs as standard of care.
The broader ophthalmic medical device market remains competitive. Major lens players including Alcon, Johnson and Johnson Vision, and Bausch + Lomb continue to invest in premium IOL platforms, and several are exploring combination drug-device approaches. SpyGlass's decision to own its manufacturing capacity rather than rely on one of those larger entities reduces the risk of a strategic conflict of interest at the supplier level.
SpyGlass was founded in 2019 as a spin-out from the University of Colorado Anschutz School of Medicine and listed on Nasdaq as SGP. The company said the acquisition does not alter its cash runway, though it did not specify the runway duration or its current cash position.